conix
2 years ago
'Novel Approach For Retinal Disease Needs' Stock Belite Bio Has 70% Potential Upside According To This Analyst
Vandana Singh
Mon, August 1, 2022
HC Wainwright initiated coverage on Belite Bio Inc (NASDAQ: BLTE) with a Buy rating and price target of $58 per ADS.
Belite Bio is focused on developing a novel once-daily oral drug for the treatment of Stargardt disease (STGD1)—a rare inherited juvenile-onset form of macular degeneration.
The lead drug candidate is LBS-008 (or Tinlarebant).
HC Wainwright says that as LBS-008 is administered orally once a day, it could be adopted rapidly by ophthalmologists and patients once the drug obtains regulatory approval, as the intravitreal injection procedure was found unpleasant.
"We believe LBS-008 has the potential to be developed as the first and best-in-class oral drug for the treatment of STGD1," the analyst writes.
The analyst expects the Phase 2 portion to report 1-year data in 2H22.
Meanwhile, the company has initiated a Phase 3 trial of LBS-008 in adolescent STGD1 in 1H22, slated to enroll approximately 60 patients. Enrollment for Phase 3 trial to complete in mid-2023.
conix
2 years ago
Belite Bio stock soars 65% in wake of strong IPO performance
May 03, 2022 12:30 PM ETBLTEBy: Val Kennedy, SA News Editor
IPO Initial Public Offering
Mikko Lemola/iStock via Getty Images
Belite Bio (BLTE) stock soared 65% on Tuesday on the heels of a strong performance last Friday following its $36M initial public offering.
Shares of the ophthalmology drug developer opened at $10.60, recently changing hands at $14.70, up 65%, at approximately $12.05 p.m. ET.
BLTE held its IPO on April 29, offering 6 million American Depositary Shares at $6 per ADS. Underwriters were granted an option to buy up to 900k additional shares ADSs at the public price. The company’s principal stockholder, Taiwan’s Lin BioScience, agreed to buy around $15M of the offering.
The stock rocketed following the IPO on Friday, reaching a session high of $17.50 before closing at $10.59, up 77% over its offering price. The stock slid 16% on Monday.
BLTE has been focused on developing treatments for eye and metabolic diseases. The company plans to use proceeds from the IPO in part to fund Phase 3 clinical testing for its drug candidate LBS-008 for Stargardt disease and further development of the product for the treatment of dry age-related macular degeneration.
News
Market Data
Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
